Fresenius Kabi submitted its first biosimilar regulatory Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®.
Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
